Register Login

Lexeo Therapeutics Inc. (LXEO)

(10% Negative) Lexeo Therapeutics Inc. (LXEO) Announces Delay in treatments Trials for cardiovascular diseases Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 7:43 p.m.

    📋 Lexeo Therapeutics Inc. (LXEO) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 11:45:40

    Event Type: Clinical Trial Update

    Event Details:

    Lexeo Therapeutics Inc. (LXEO) Announces Clinical Trial Update Lexeo Therapeutics Inc. (LXEO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: treatments, trends
    • Diseases/Conditions: cardiovascular diseases, transd
    • Clinical Stage: clinical trial, Phase I
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Lexeo Therapeutics, Inc.
      • expected in 2026

    🔬 Clinical Development Pipeline (Lexeo Therapeutics Inc.):

    Product Type Development Stage Therapeutic Area Source
    LX2020 GENETIC Phase PHASE1 Arrhythmogenic Cardiomyopathy ClinicalTrials.gov
    High Dose LX2006 GENETIC Phase PHASE1 Friedreich Ataxia ClinicalTrials.gov
    Mid Dose LX2006 GENETIC Phase PHASE1 Friedreich Ataxia ClinicalTrials.gov
    Low dose LX2006 GENETIC Phase PHASE1 Friedreich Ataxia ClinicalTrials.gov
    LX1001 BIOLOGICAL Phase PHASE1 Alzheimer Disease ClinicalTrials.gov
    GLYC-101 Placebo DRUG Phase PHASE2 Wounds ClinicalTrials.gov
    GLYC-101 Gel (1.0%) DRUG Phase PHASE2 Wounds ClinicalTrials.gov
    GLYC-101 Gel (0.1%) DRUG Phase PHASE2 Wounds ClinicalTrials.gov
    20% VDA-1102 DRUG Phase PHASE2 Actinic Keratosis ClinicalTrials.gov
    10% VDA-1102 DRUG Phase PHASE2 Actinic Keratosis ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Alopecia, Androgenetic ClinicalTrials.gov
    TDM-105795 DRUG Phase PHASE1 Alopecia, Androgenetic ClinicalTrials.gov
    GLYC-101 gel (1.0 %) DRUG Phase PHASE1 Wounds ClinicalTrials.gov
    Placebo gel DRUG Phase PHASE1 Wounds ClinicalTrials.gov
    9.6 mg intranasal carbetocin DRUG Phase PHASE3 Prader-Willi Syndrome ClinicalTrials.gov
    3.2 mg intranasal carbetocin DRUG Phase PHASE3 Prader-Willi Syndrome ClinicalTrials.gov
    UHE-103A2B cream DRUG Phase PHASE2 Tinea Pedis ClinicalTrials.gov
    UHE-103A1B cream DRUG Phase PHASE2 Tinea Pedis ClinicalTrials.gov
    UHE-103B cream DRUG Phase PHASE2 Tinea Pedis ClinicalTrials.gov
    UHE-103A2 cream DRUG Phase PHASE2 Tinea Pedis ClinicalTrials.gov
    UHE-103A1 cream DRUG Phase PHASE2 Tinea Pedis ClinicalTrials.gov
    Human Cadaver Allograft BIOLOGICAL Phase PHASE1 Deep Full-thickness Burn Injury (Disorder) ClinicalTrials.gov
    realSKIN (skin xenotransplant) BIOLOGICAL Phase PHASE1 Deep Full-thickness Burn Injury (Disorder) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Lexeo Therapeutics Inc.
    • Ticker Symbol: LXEO

Search

News categories